本帖最后由 老马 于 2012-1-13 21:20 编辑 ; }) e$ ~% T ~/ Y4 M) j
+ g; f E# R9 J% ?8 K4 }3 r& A
爱必妥和阿瓦斯丁的比较
( G+ ?, e. q; f8 F
, d0 r7 e @9 O$ C' P, \0 Ihttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/$ G, q2 m8 b8 K! e: `$ K
" k y- O# B9 ^6 c
" z. C8 Z- m! dhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/5 a0 S" _3 D& \+ O& ?2 H4 o4 q: a3 U
==================================================
5 y: r G/ }+ q& v& }9 {Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
8 w+ T# P, U. u, C( f. s7 |# UPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
8 q! ~2 a" ]5 w/ OResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
6 w+ n9 V: m& g# |3 k! S% v8 U$ g. i
|
显身卡
